查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1477111

非病毒药物传输系统市场，按分子、生物製剂、治疗领域、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Non-Viral Drug Delivery Systems Market, By Molecules, By Biologics, By Therapeutic Area, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023 年非病毒药物输送系统市场规模为 71.23 亿美元，2024 年至 2032 年复合年增长率为 12.5%。

非病毒药物传输系统市场-市场动态

癌症盛行率上升推动市场需求

全球癌症盛行率的不断上升预计将在预测期内推动市场成长。例如，根据世界卫生组织预测，到 2022 年，预计将有 2,000 万新发癌症病例和 970 万人死于该疾病。五分之一的人会在一生中的某个阶段罹患癌症；九分之一的男性和十二分之一的女性将死于这种疾病。

非病毒药物传输系统市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 12.5% 左右的复合年增长率成长

根据分子，小分子细分市场预计在预测期内将以最高复合年增长率成长

根据治疗领域细分，肿瘤疾病领域预计将在预测期内引领市场

按地区划分，北美是 2023 年的主要收入来源

非病毒药物传输系统市场区隔分析：

全球非病毒药物传输系统市场根据分子、生物製剂、治疗领域和地区进行细分。

根据分子，市场分为小分子和大分子。预计小分子细分市场在预测期内将以最高复合年增长率成长。随着科学家和製药公司寻找创新方法来改善小分子药物治疗一系列疾病的输送和有效性，小分子非病毒药物输送系统的市场预计将继续成长。

依治疗领域，该产业分为传染病、肿瘤疾病、遗传疾病、神经系统疾病、肝臟疾病、心血管疾病等。预计肿瘤疾病领域将在预测期内引领市场。该细分市场的扩张归因于癌症盛行率的上升。

非病毒药物传输系统市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。预计北美将在预测期内主导市场。区域市场的扩张归因于慢性病的高盛行率。此外，研发支出的高额也是推动该地区市场成长的重要因素。

非病毒药物输送系统市场-竞争格局：

市场的主要参与者包括 Arcturus Therapeutics、Bio-Path Holdings、CureVac、Entos Pharmaceuticals、eTheRNA、Matinas BioPharma、MDimune 和 PCI Biotech。这些参与者采取了多种策略来获取最大的市场份额，例如产品发布、收购、扩张等。

目录

第 1 章：非病毒药物传输系统市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 非病毒药物传输系统市场分子片段
    • 生物製品的非病毒药物传输系统市场片段
    • 按治疗领域分類的非病毒药物传输系统市场片段
    • 按国家/地区分類的非病毒药物传输系统市场片段
    • 按地区分類的非病毒药物传输系统市场片段
  • 竞争洞察

第 3 章：非病毒药物传输系统主要市场趋势

  • 非病毒药物传输系统市场驱动因素
    • 市场驱动因素的影响分析
  • 非病毒药物传输系统市场限制
    • 市场限制影响分析
  • 非病毒药物传输系统市场机会
  • 非病毒药物传输系统市场未来趋势

第 4 章：非病毒药物输送系统产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：非病毒药物传输系统市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：非病毒药物传输系统市场格局

  • 2023 年非病毒给药系统市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：非病毒药物输送系统市场 - 按分子

  • 概述
    • 按分子分類的细分市场占有率分析
    • 小分子
    • 大分子

第 8 章：非病毒药物传输系统市场 - 依生物製剂

  • 概述
    • 按生物製品分類的细分市场占有率分析
    • RNAi/mRNA
    • DNA寡核苷酸
    • 抗体
    • 蛋白质/胜肽

第 9 章：非病毒药物传输系统市场 - 按治疗领域

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 传染性疾病
    • 肿瘤疾病
    • 遗传性疾病
    • 神经系统疾病
    • 肝臟疾病
    • 心血管疾病
    • 其他的

第 10 章：非病毒药物传输系统市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美非病毒药物传输系统主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按分子）
    • 北美生物製剂市场规模与预测
    • 北美市场规模与预测（按治疗领域）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲非病毒药物传输系统主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按分子）
    • 欧洲生物製剂市场规模与预测
    • 欧洲市场规模与预测（按治疗领域）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区非病毒药物传输系统主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 按分子分類的亚太市场规模和预测
    • 亚太地区生物製剂市场规模与预测
    • 按治疗领域分類的亚太市场规模和预测
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲非病毒药物传输系统主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按分子）
    • 拉丁美洲生物製剂市场规模与预测
    • 拉丁美洲市场规模与预测（按治疗领域）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲非病毒药物传输系统主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按分子）
    • 中东及非洲生物製品市场规模及预测
    • 中东和非洲市场规模及预测（按治疗领域）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 非病毒药物输送系统产业

  • 竞争仪表板
  • 公司简介
    • Arcturus Therapeutics
    • Bio-Path Holdings
    • CureVac
    • Entos Pharmaceuticals
    • eTheRNA
    • Matinas BioPharma
    • MDimune
    • PCI Biotech

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究治疗领域学
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2507

REPORT HIGHLIGHT

Non-Viral Drug Delivery Systems Market size was valued at USD 7,123 Million in 2023, expanding at a CAGR of 12.5% from 2024 to 2032.

Systems for delivering therapeutic agents-such as medications, DNA, or proteins-into the body without the use of viral vectors are referred to as non-viral drug delivery systems. Non-viral delivery systems use a variety of artificial or natural carriers to deliver therapeutic payloads, in contrast to viral vectors that use viruses to insert genetic information into cells. These carriers can target particular cells or tissues, improve stability, shield the payload from deterioration, and make it easier for it to be released at the intended location of action.

Non-Viral Drug Delivery Systems Market- Market Dynamics

Increasing prevalence of cancer to propel market demand

The increasing prevalence of cancer across the globe is expected to drive market growth during the forecast period. For instance, according to the World Health Organization, 20 million new instances of cancer and 9.7 million deaths from the disease are predicted for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will pass away from the illness.

Non-Viral Drug Delivery Systems Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2024-2032)

Based on molecule, the small molecules segment is expected to grow at the highest CAGR during the forecast period

Based on therapeutic area segmentation, the Oncological Disorders segment is expected to lead the market over the projected period

Based on region, North America was the leading revenue generator in 2023

Non-Viral Drug Delivery Systems Market- Segmentation Analysis:

The Global Non-Viral Drug Delivery Systems Market is segmented based on Molecules, Biologics, Therapeutic Area, and Region.

Based on the molecules, the market is categorized into Small Molecules and Large Molecules. The Small Molecules segment is expected to grow at the highest CAGR during the forecast period. As scientists and pharmaceutical firms look for innovative ways to improve the delivery and effectiveness of small molecule medications for a range of illnesses and ailments, the market for non-viral drug delivery systems for small molecules is expected to continue growing.

Based on the therapeutic area, the industry is divided into Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Others. The Oncological Disorders segment is expected to lead the market over the projected period. The segment expansion is attributed to the rising prevalence of cancer.

Non-Viral Drug Delivery Systems Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period. The regional market expansion is attributed to the high prevalence of chronic disease. Moreover, the high spending on R&D is also an important factor propelling the market growth in the region.

Non-Viral Drug Delivery Systems Market- Competitive Landscape:

The key players operating in the market include Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA, Matinas BioPharma, MDimune and PCI Biotech. These players adopted several strategies to capture the maximum market share such as product launch, acquisition, expansion and others.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Arcturus Therapeutics

Bio-Path Holdings

CureVac

Entos Pharmaceuticals

eTheRNA

Matinas BioPharma

MDimune

PCI Biotech

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY MOLECULES- MARKET ANALYSIS, 2019 - 2032

  • Small Molecules
  • Large Molecules

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY BIOLOGICS- MARKET ANALYSIS, 2019 - 2032

  • RNAi / mRNA
  • DNA Oligonucleotides
  • Antibodies
  • Proteins / Peptides

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Oncological Disorders
  • Genetic Disorders
  • Neurological Disorders
  • Hepatic Disorders
  • Cardiovascular Disorders
  • Others

GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Non-Viral Drug Delivery Systems Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Non-Viral Drug Delivery Systems Market Snippet by Molecules
    • 2.1.2.Non-Viral Drug Delivery Systems Market Snippet by Biologics
    • 2.1.3.Non-Viral Drug Delivery Systems Market Snippet by Therapeutic Area
    • 2.1.4.Non-Viral Drug Delivery Systems Market Snippet by Country
    • 2.1.5.Non-Viral Drug Delivery Systems Market Snippet by Region
  • 2.2.Competitive Insights

3.Non-Viral Drug Delivery Systems Key Market Trends

  • 3.1.Non-Viral Drug Delivery Systems Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Non-Viral Drug Delivery Systems Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Non-Viral Drug Delivery Systems Market Opportunities
  • 3.4.Non-Viral Drug Delivery Systems Market Future Trends

4.Non-Viral Drug Delivery Systems Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Non-Viral Drug Delivery Systems Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Non-Viral Drug Delivery Systems Market Landscape

  • 6.1.Non-Viral Drug Delivery Systems Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Non-Viral Drug Delivery Systems Market - By Molecules

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Molecules, 2023 & 2032 (%)
    • 7.1.2.Small Molecules
    • 7.1.3.Large Molecules

8.Non-Viral Drug Delivery Systems Market - By Biologics

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Biologics, 2023 & 2032 (%)
    • 8.1.2.RNAi / mRNA
    • 8.1.3.DNA Oligonucleotides
    • 8.1.4.Antibodies
    • 8.1.5.Proteins / Peptides

9.Non-Viral Drug Delivery Systems Market - By Therapeutic Area

  • 9.1.Overview
    • 9.1.1.Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 9.1.2.Infectious Diseases
    • 9.1.3.Oncological Disorders
    • 9.1.4.Genetic Disorders
    • 9.1.5.Neurological Disorders
    • 9.1.6.Hepatic Disorders
    • 9.1.7.Cardiovascular Disorders
    • 9.1.8.Others

10.Non-Viral Drug Delivery Systems Market- By Geography

  • 10.1.Introduction
    • 10.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2.North America
    • 10.2.1.Overview
    • 10.2.2.Non-Viral Drug Delivery Systems Key Manufacturers in North America
    • 10.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4.North America Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.2.5.North America Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.2.6.North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.2.7.U.S.
      • 10.2.7.1.Overview
      • 10.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3.U.S. Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.2.7.4.U.S. Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.2.7.5.U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.2.8.Canada
      • 10.2.8.1.Overview
      • 10.2.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3.Canada Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.2.8.4.Canada Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.2.8.5.Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.3.Europe
    • 10.3.1.Overview
    • 10.3.2.Non-Viral Drug Delivery Systems Key Manufacturers in Europe
    • 10.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4.Europe Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.3.5.Europe Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.3.6.Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.7.Germany
      • 10.3.7.1.Overview
      • 10.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3.Germany Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.7.4.Germany Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.7.5.Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.8.Italy
      • 10.3.8.1.Overview
      • 10.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3.Italy Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.8.4.Italy Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.8.5.Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.9.United Kingdom
      • 10.3.9.1.Overview
      • 10.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3.United Kingdom Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.9.4.United Kingdom Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.9.5.United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.10.France
      • 10.3.10.1.Overview
      • 10.3.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3.France Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.10.4.France Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.10.5.France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.11.Russia
      • 10.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2.Russia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.11.3.Russia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.11.4.Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.12.Netherlands
      • 10.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2.Netherlands Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.12.3.Netherlands Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.12.4.Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.13.Sweden
      • 10.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2.Sweden Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.13.3.Sweden Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.13.4.Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.14.Poland
      • 10.3.14.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2.Poland Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.14.3.Poland Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.14.4.Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.3.15.Rest of Europe
      • 10.3.15.1.Overview
      • 10.3.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3.Rest of the Europe Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.3.15.4.Rest of the Europe Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.3.15.5.Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.4.Asia Pacific (APAC)
    • 10.4.1.Overview
    • 10.4.2.Non-Viral Drug Delivery Systems Key Manufacturers in Asia Pacific
    • 10.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4.Asia Pacific Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.4.5.Asia Pacific Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.4.6.Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.7.India
      • 10.4.7.1.Overview
      • 10.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3.India Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.7.4.India Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.7.5.India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.8.China
      • 10.4.8.1.Overview
      • 10.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3.China Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.8.4.China Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.8.5.China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.9.Japan
      • 10.4.9.1.Overview
      • 10.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3.Japan Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.9.4.Japan Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.9.5.Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.10.South Korea
      • 10.4.10.1.Overview
      • 10.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3.South Korea Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.10.4.South Korea Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.10.5.South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.11.Australia
      • 10.4.11.1.Overview
      • 10.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3.Australia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.11.4.Australia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.11.5.Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.12.Thailand
      • 10.4.12.1.Overview
      • 10.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3.Thailand Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.12.4.Thailand Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.12.5.Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.13.Indonesia
      • 10.4.13.1.Overview
      • 10.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3.Indonesia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.13.4.Indonesia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.13.5.Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.14.Philippines
      • 10.4.14.1.Overview
      • 10.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3.Philippines Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.14.4.Philippines Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.14.5.Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.4.15.Rest of APAC
      • 10.4.15.1.Overview
      • 10.4.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3.Rest of APAC Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.4.15.4.Rest of APAC Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.4.15.5.Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.5.Latin America
    • 10.5.1.Overview
    • 10.5.2.Non-Viral Drug Delivery Systems Key Manufacturers in Latin America
    • 10.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4.Latin America Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.5.5.Latin America Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.5.6.Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.7.Brazil
      • 10.5.7.1.Overview
      • 10.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3.Brazil Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.7.4.Brazil Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.7.5.Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.8.Mexico
      • 10.5.8.1.Overview
      • 10.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3.Mexico Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.8.4.Mexico Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.8.5.Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.9.Argentina
      • 10.5.9.1.Overview
      • 10.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3.Argentina Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.9.4.Argentina Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.9.5.Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.10.Colombia
      • 10.5.10.1.Overview
      • 10.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3.Colombia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.10.4.Colombia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.10.5.Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.5.11.Rest of LATAM
      • 10.5.11.1.Overview
      • 10.5.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3.Rest of LATAM Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.5.11.4.Rest of LATAM Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.5.11.5.Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 10.6.Middle East and Africa
    • 10.6.1.Overview
    • 10.6.2.Non-Viral Drug Delivery Systems Key Manufacturers in Middle East and Africa
    • 10.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4.Middle East and Africa Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
    • 10.6.5.Middle East and Africa Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
    • 10.6.6.Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.7.Saudi Arabia
      • 10.6.7.1.Overview
      • 10.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3.Saudi Arabia Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.7.4.Saudi Arabia Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.7.5.Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.8.United Arab Emirates
      • 10.6.8.1.Overview
      • 10.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3.United Arab Emirates Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.8.4.United Arab Emirates Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.8.5.United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.9.Israel
      • 10.6.9.1.Overview
      • 10.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3.Israel Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.9.4.Israel Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.9.5.Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.10.Turkey
      • 10.6.10.1.Overview
      • 10.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3.Turkey Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.10.4.Turkey Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.10.5.Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.11.Algeria
      • 10.6.11.1.Overview
      • 10.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3.Algeria Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.11.4.Algeria Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.11.5.Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.12.Egypt
      • 10.6.12.1.Overview
      • 10.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3.Egypt Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.12.4.Egypt Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.12.5.Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 10.6.13.Rest of MEA
      • 10.6.13.1.Overview
      • 10.6.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3.Rest of MEA Market Size and Forecast, By Molecules, 2019 - 2032 (US$ Million)
      • 10.6.13.4.Rest of MEA Market Size and Forecast, By Biologics, 2019 - 2032 (US$ Million)
      • 10.6.13.5.Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)

11.Key Vendor Analysis- Non-Viral Drug Delivery Systems Industry

  • 11.1.Competitive Dashboard
  • 11.2.Company Profiles
    • 11.2.1.Arcturus Therapeutics
    • 11.2.2.Bio-Path Holdings
    • 11.2.3.CureVac
    • 11.2.4.Entos Pharmaceuticals
    • 11.2.5.eTheRNA
    • 11.2.6.Matinas BioPharma
    • 11.2.7.MDimune
    • 11.2.8.PCI Biotech

12.360 Degree Analyst View

13.Appendix

  • 13.1.Research Therapeutic Areaology
  • 13.2.References
  • 13.3.Abbreviations
  • 13.4.Disclaimer
  • 13.5.Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Non-Viral Drug Delivery Systems Market: Molecules Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Molecules
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Molecules 2019-2032 (USD Million)
  • TABLE Non-Viral Drug Delivery Systems Market: Biologics Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Biologics
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Biologics 2019-2032 (USD Million)
  • TABLE Non-Viral Drug Delivery Systems Market: Therapeutic AreaSnapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Area
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Therapeutic Area2019-2032 (USD Million)
  • TABLE Non-Viral Drug Delivery Systems Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Non-Viral Drug Delivery Systems Market, by Region 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE North America Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Europe Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Asia Pacific Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Latin America Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Molecules, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Biologics, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Non-Viral Drug Delivery Systems Market, by Therapeutic Area, 2019-2032 (USD Million)